Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0027819 (
neuroblastoma
)
27,800
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The aim of this study was to investigate the mechanism by which short-term pretreatment with the phorbol ester 12-O-tetradecanoylphorbol 13-acetate (TPA; 100 nM) enhances
noradrenaline
(NA) release from the human
neuroblastoma
cell line SH-SY5Y. Subcellular fractionation and immunocytochemical studies demonstrated that an 8-min TPA treatment caused translocation of the alpha-subtype of protein kinase C (PKC) from the cytosol to the plasma membrane. In contrast, TPA altered the distribution of PKC-epsilon from cytosolic and membrane-associated to cytoskeleton- and membrane-associated. TPA had no effect on the cytosolic location of PKC-zeta. Subcellular fractionation studies also showed that the myristoylated alanine-rich C-kinase substrate (MARCKS), a major neuronal PKC substrate that has been implicated in the mechanism of neurotransmitter release, translocated from membranes to cytosol in response to an 8-min TPA treatment. Under these conditions the level of phosphorylation of MARCKS increased threefold. The ability of TPA to enhance NA release and to cause the translocation and phosphorylation of MARCKS was inhibited by the PKC inhibitor Ro 31-8220 (10 microM). Selective down-regulation of PKC subtypes by prolonged exposure to phorbol 12,13-dibutyrate (100 nM) attenuated the TPA-induced enhancement of NA release and the translocation of MARCKS over an interval similar to that of down-regulation of PKC-alpha (but not -epsilon or -zeta). Thus, we have demonstrated a strong correlation between the translocation of MARCKS and the enhancement of NA release from SH-SY5Y cells due to the TPA-induced activation of PKC-alpha.
...
PMID:Activation of protein kinase C-alpha and translocation of the myristoylated alanine-rich C-kinase substrate correlate with phorbol ester-enhanced noradrenaline release from SH-SY5Y human neuroblastoma cells. 897 51
Western blot analysis showed that the human
neuroblastoma
SH-SY5Y expresses the proteins synaptotagmin l, synaptobrevin, synapsin-l, rab3a, syntaxin, SNAP-25, NSF, alpha-SNAP, and munc-18, which have been implicated in the movement, docking, and fusion of vesicles during exocytosis from other neuroendocrine cells. The subcellular localization of secretogranins I and II, synaptotagmin l, neuropeptide Y, rab3a, synaptobrevin, synaptophysin, and syntaxin was investigated by immunofluorescence microscopy and revealed punctate staining patterns characteristic of secretory vesicles. The comigration of
noradrenaline
, secretogranin II, and dopamine-beta-hydroxylase on sucrose-D2O gradient fractions indicates the presence of a population of
noradrenaline
-containing large dense-cored vesicles (LDCVs). In addition, a lighter vesicle population is also present that does not appear to be noradrenergic and contains a 48-kDa synaptophysin antigen absent from the large dense-cored vesicles. Immunocytochemical experiments show that not all of the vesicles that express synaptotagmin l contain secretogranin II. Thus, our studies suggest that two types of vesicle are present in SH-SY5Y cells, one of which, the LDCVs, contains
noradrenaline
. These findings confirm our previous studies suggesting that depolarization-evoked release of
noradrenaline
from SH-SY5Y occurs by LDCV exocytosis. This enhances the value of SH-SY5Y as a cell line in which to study the mechanism by which
noradrenaline
release is regulated.
...
PMID:Occurrence of two types of secretory vesicles in the human neuroblastoma SH-SY5Y. 908 25
Exposure of human
neuroblastoma
SH-SY5Y cells to 300 nM neuropeptide Y (NPY) or 1 microM muscarine separately failed to evoke release of [3H]
noradrenaline
([3H]NA). Both agonists, however, induced a modest rise in [Ca2+]i. When NPY and muscarine were applied simultaneously, the rise in [Ca2+]i was greater than the sum of the rises of either agonist applied alone, and also evoked [3H]NA release, NPY evoked a rise in [Ca2+]i when applied during prolonged exposure to muscarine, although the peak level of [Ca2+]i was significantly lower (p < 0.05) than that reached following simultaneous application, and [3H]NA release was not stimulated. Simultaneous exposure of SH-SY5Y cells to muscarine and NPY thus induces a greater than additive rise in [Ca2+]i exceeding a critical level required to evoke [3H]NA release.
...
PMID:Neuropeptide Y elevates intracellular Ca2+ and evokes noradrenaline release in SH-SY5Y cells. 911 8
In this paper we report the effects of the
neuroblastoma
-seeking agent meta-iodobenzylguanidine (MIBG) on NADH-driven superoxide formation and NADH-driven lipid peroxidation in beef heart submitochondrial particles. MIBG is a structural analogue of
noradrenaline
and is capable of inhibiting complex I and complex III of the respiratory chain. The results of our studies show that MIBG enhanced both NADH-driven superoxide formation and NADH-driven lipid peroxidation at concentrations that are likely to exist inside mitochondria of the target cells of
neuroblastoma
patients treated with [131I]MIBG. The effect of MIBG is comparable to that of rotenone (an inhibitor of complex I) rather than that of antimycin (an inhibitor of complex III). These results suggest that the formation of superoxide and lipid peroxidation contributes to the cytotoxicity of [131I]MIBG.
...
PMID:The effect of the neuroblastoma-seeking agent meta-iodobenzylguanidine (MIBG) on NADH-driven superoxide formation and NADH-driven lipid peroxidation in beef heart submitochondrial particles. 915 26
The voltage-dependent inhibition of single N-type Ca(2+) channels by
noradrenaline
(NA) and the delta-opioid agonist D-Pen(2)-D-Pen (5)-enkephalin (DPDPE) was investigated in cell-attached patches of human
neuroblastoma
IMR32 cells with 100 mM Ba(2+) and 5 microM nifedipine to block L-type channels. In 70% of patches, addition of 20 microM NA + 1 microM DPDPE delayed markedly the first channel openings, causing a four- to fivefold increase of the first latency at +20 mV. The two agonists or NA alone decreased also by 35% the open probability (P(o)), prolonged partially the mean closed time, and increased the number of null sweeps. In contrast, NA + DPDPE had little action on the single-channel conductance (19 versus 19.2 pS) and minor effects on the mean open time. Similarly to macroscopic Ba(2+) currents, the ensemble currents were fast activating at control but slowly activating and depressed with the two agonists. Inhibition of single N-type channels was effectively removed (facilitated) by short and large depolarizations. Facilitatory pre-pulses increased P(o) significantly and decreased fourfold the first latency. Ensemble currents were small and slowly activating before pre-pulses and became threefold larger and fast decaying after facilitation. Our data suggest that slowdown of Ca(2+) channel activation by transmitters is mostly due to delayed transitions from a modified to a normal (facilitated) gating mode. This single-channel gating modulation could be well simulated by a Monte Carlo method using previously proposed kinetic models predicting marked prolongation of first channel openings.
...
PMID:Voltage-dependent modulation of single N-Type Ca2+ channel kinetics by receptor agonists in IMR32 cells. 917 38
Transporters for the monoamine neurotransmitters, including
noradrenaline
, 5-hydroxytryptamine [5-HT] and dopamine, have twelve transmembrane spanning regions and cotransport Na+ and Cl- ions. Another family of Na(+)-dependent transporters is that containing the Na+/glucose and Na+/proline cotransporters that are found in the epithelial cells of renal and intestinal brush border membranes. It has been shown that various trivalent lanthanides can substitute for Na+ for transport of glucose and proline. The aim of this study was to determine the effects of lanthanides on the activities of the human
noradrenaline
, 5-HT and dopamine transporters. Cultured cells were incubated for 2 min with 10 nM 3H-
noradrenaline
(SK-N-SH-SY5Y human
neuroblastoma
cells), 3H-5-HT (JAR human placental choriocarcinoma cells) or 3H-dopamine (COS-7 cells transfected with the cDNA of the human dopamine transporter). Specific amine uptake was determined as the difference between accumulation of the amine in the cells in the absence and presence of a corresponding uptake inhibitor. Under both isotonic (150 mM NaCl or LiCl or 90 mM lanthanide salt) and hypertonic (150 mM NaCl +100 mM LiCl, 250 mM LiCl or 150 mM lanthanide salt) conditions, replacement of Na+ by Li+, La3+, Eu3+ or Sm3+ abolished the specific uptake of
noradrenaline
in SK-N-SH-SY5Y cells and replacement of Na+ by Li+ or Eu3+ decreased the specific uptake of 5-HT in JAR cells by 94-100% and that of dopamine in transfected COS-7 cells by 95-99%. The direct effects of Eu3+ (with Na+ present) on the human noradrenaline transporter in SK-N-SH-SY5Y cells were also examined. Eu3+ inhibited
noradrenaline
uptake into the cells (IC50 2.6 mM) and nisoxetine binding to crude membranes of SK-N-SH-SY5Y cells (IC50 4.7 mM) with similar potencies. Further experiments showed that 4.5 mM EuCl3 in the presence of 150 mM Na+ caused a 3.5-fold increase in the K(m) of
noradrenaline
and no change in the maximal rate of
noradrenaline
uptake. EuCl3 (4.5 mM) also caused a pronounced inhibition of the Na(+)-dependent stimulation of
noradrenaline
uptake by SK-N-SH-SY5Y cells. It can be concluded from these data that, in contrast with the Na+/glucose and Na+/proline cotransporters, the lanthanides cannot substitute for Na+ in the transport of substrates by the monoamine neurotransmitter transporters and that the lanthanides inhibit the latter transporters by interacting with sites of the transporters involved in amine and Na+ binding.
...
PMID:Lanthanides inhibit the human noradrenaline, 5-hydroxytryptamine and dopamine transporters. 920 53
Neuropeptide Y (NPY) is a peptide hormone that is expressed, stored, and released in sympathetic neurones together with
noradrenaline
. Elevated plasma concentrations of NPY have been reported in patients with neural crest tumors (
neuroblastoma
, pheochromocytoma) and following exercise. We studied plasma concentrations of NPY in children and adults with chronic and terminal renal failure and compared them with those in healthy controls. Neuropeptide Y was significantly higher in children and adolescents receiving peritoneal dialysis (5.3 +/- 2.8 pmol/L; n = 11 [mean +/- SD]) or hemodialysis (5.4 +/- 2.1 pmol/L; n = 14) than in healthy children (2.3 +/- 0.9 pmol/L; n = 19) or pediatric patients with impaired renal function who are not receiving dialysis (2.7 +/- 0.6 pmol/L; n = 8; mean glomerular filtration rate, 41 mL/min x 1.73 m2). There was a small but insignificant negative correlation between glomerular filtration rate and NPY concentrations in children with impaired renal function (r = 0.49; P = 0.25). In healthy adults, NPY concentration was similar to that in healthy children (1.8 +/- 1.0 pmol/L; n = 13), and it was significantly elevated in adults receiving hemodialysis (5.9 +/- 1.7 pmol/L; n = 16). No significant changes in NPY concentrations were found before and after hemodialysis in pediatric or adult patients. We conclude that plasma concentrations of NPY are elevated in patients with chronic renal failure who are receiving either peritoneal or hemodialysis, but not in patients with moderately impaired renal function. Whether elevated NPY concentration indicates increased sympathetic activity or is caused by reduced NPY clearance remains to be shown.
...
PMID:Elevated plasma concentrations of neuropeptide Y in children and adults with chronic and terminal renal failure. 921 97
An analogue of meta-iodobenzylguanidine (MIBG) in which an aromatic hydrogen was replaced with fluorine has been found to possess many properties similar to those of the parent compound. Moreover, 4-fluoro-3-iodobenzylguanidine (FIBG) was retained in vitro by human
neuroblastoma
cells to a much greater extent than MIBG itself. Since alpha-emitters such as 211At could be valuable for the treatment of micrometastatic disease, an FIBG analogue in which the iodine atom is replaced by 211At would be of interest. In this study, we have evaluated the in vitro and in vivo properties of 3-[211At]astato-4-fluorobenzylguanidine ([211At]AFBG). The specific binding of [211At]AFBG to SK-N-SH human
neuroblastoma
cells remained fairly constant over 2- to 3-log activity range and was similar to that of [131I]MIBG. The uptake of [211At]AFBG by this cell line was reduced by desipramine, ouabain, 4 degrees C incubation,
noradrenaline
, unlabelled MIBG and FIBG, suggesting that its uptake is specifically mediated through an active uptake-1 mechanism. Over the 16 h period studied, the amount of [211At]AFBG retained was similar to that of [131I]FIBG, whereas the per cent of retained meta-[211At]astatobenzylguanidine ([211At]MABG) was considerably less than that of [131I]FIBG (53% vs 75%; P < 0.05). The IC50 values for the inhibition of uptake of [131I]MIBG, [211At]MABG, [125I]FIBG and [211At]AFBG by unlabelled MIBG were 209, 300, 407 and 661 nM respectively, suggesting that the affinities of these tracers for the noradrenaline transporter in SK-N-SH cells increase in that order. Compared with [211At]MABG, higher uptake of [211At]AFBG was seen in vivo in normal mouse target tissues such as heart and, to a certain extent, in adrenals. That the uptake of [211At]AFBG in these tissues was related to the uptake-1 mechanism was demonstrated by its reduction when mice were pretreated with desipramine. However, the stability of [211At]AFBG towards in vivo dehalogenation was less than that of [211At]MABG, as evidenced by the higher uptake of 211At in thyroid, spleen, lungs and stomach.
...
PMID:3-[211At]astato-4-fluorobenzylguanidine: a potential therapeutic agent with prolonged retention by neuroblastoma cells. 923 23
We have examined the effects of the volatile general anaesthetic agent, halothane, on K+ and carbachol stimulated [3H]
noradrenaline
release and associated increases in intracellular Ca2+ in a cultured human
neuroblastoma
cell line, SH-SY5Y. K+ (but not carbachol) stimulated [3H]
noradrenaline
release, and the increase in intracellular Ca2+ concentration was entirely extracellular Ca2+ dependent. Halothane produced a dose-dependent reduction in K+ evoked release of [3H]
noradrenaline
with significant inhibition (17%) occurring from 1.26 atm%. Basal and carbachol evoked release were unaffected. Halothane also produced a dose-dependent reduction in K+ evoked increases (measured at the peak) in intracellular Ca2+ with significant inhibition (29%) occurring from 0.88 atm%. K+ plateau, basal and carbachol evoked increases in intracellular Ca2+ were unaffected. These data suggest that halothane reduced Ca2+ entry through voltage-sensitive Ca2+ channels and implicate this important class of ion channel in the mechanism of anaesthesia.
...
PMID:Effect of halothane on K+ and carbachol stimulated [3H]noradrenaline release and increased [Ca2+]i in SH-SY5Y human neuroblastoma cells. 930 93
It is proposed that the prerequisites for a low-risk to major cancers-breast, colon, lung, prostate, melanoma (as, for example in Africans, Chinese and Japanese) - include upregulated hypothalamic dopaminergic activity compared to depressed noradrenergic/thyrogenic function and raised vagal tone, and a neuroendocrine constellation that promotes improved immune efficiency and its inimical to the onset of aversive cell responses. Since the integrity of these tissues is regulated by hypothalamic-hypophyseal hormones, under tonic dopaminergic inhibition, cancers are potentially preventable as long as dopaminergic integrity is maintained, or the decline in ageing in slowed. Evidence for the impact of upregulated dopamine on tumour prevention includes: (1) a reduced (40%) rate of colonic cancer in exercised-trained ageing subjects; (2) reduced expected rates of lung/colon cancers, and skin tumours in prolonged post-menopausal oestrogen replacement; (3) the virtual suppression of all cancers during pregnancy (when dopamine synthesis increases); (4) the low rate of bronchogenic carcinoma correlates with reduced enzymatic conversion of dopamine to
noradrenaline
; and (5)
neuroblastoma
(specifically dopamine dysregulated tumour) regresses spontaneously on dopamine normalization. Similar tumour reduction is anticipated by controlling the intake of calories. The subtlety of the switch to upregulated dopamine, the speed of translation at the cellular level and the sustainability of responses as long as the initiating stimulus persists (as exposed by pregnancy), underline the plasticity of the neuroendocrine mechanism and ease of manipulation. Long exposure to environmental iodine deficiency, as seen for example in Africans and Chinese, reveals a crucial dopamine-thyroid action that slows cell timing mechanisms. The common neurohormonal basis identified for the prevention of human cancers has practical application, with reasonably assured positive results.
...
PMID:Major human cancers are preventable: physiological stimuli induce a dopamine-thyroid-immune efficient mechanism. 930 74
<< Previous
1
2
3
4
5
6
7
8
9
10